natgillin/translations-raw huggingface dataset:
The CHMP decided that Pegasys’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Pegasys večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that PegIntron’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila PegIntron večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Pergoveris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Pergoveris večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Peyona’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Peyona večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that PhotoBarr’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila PhotoBarr večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Plavix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Plavix večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Possia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Possia večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Pregabalin Pfizer’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Pregabalin Pfizer večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Preotact’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Preotact večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor je zaključil, da so koristi zdravila Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Prepandrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi cepiva Prepandrix večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Prevenar 13’s benefits are greater than its risks and recommended that it be granted marketing authorisation.
CHMP je zaključil, da so koristi zdravila Prevenar 13 večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Prevenar’s benefits are greater than its risks and recommended that Prevenar be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Prevenar večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Prezista’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Prezista večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that PritorPlus’s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone.
CHMP je zaključil, da so koristi zdravila PritorPlus pri zdravljenju esencialne hipertenzije pri bolnikih, katerih krvni tlak ni zadostno uravnan samo s telmisartanom, večje od z njim povezanih tveganj.
The CHMP decided that Pritor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Pritor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Prolia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Prolia večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that ProQuad’s benefits are greater than its risks and recommended that it be given marketing authorisation for use in children above 12 months of age, noting that a second vaccination against chickenpox should be given for full protection against the disease.
CHMP je zaključil, da so koristi cepiva ProQuad večje od z njim povezanih tveganj in priporočil, da se zanj odobri dovoljenje za promet za uporabo pri otrocih, starejših od 12 mesecev, pri čemer je proti noricam potreben drugi odmerek cepiva, da se zagotovi popolna zaščita proti tej bolezni.
The CHMP decided that Protaphane’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Protaphane večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Protelos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Protelos večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Protopic’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Protopic večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Rapamune’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Rapamune večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rapilysin’s benefits are greater than its risks for and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Rapilysin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rapiscan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rapiscan večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rasilamlo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rasilamlo večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rasilez HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rasilez HCT večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rebetol’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rebetol večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rebif’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Rebif večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Regranex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Regranex večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Relistor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Relistor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Remicade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Remicade večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Renagel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Renagel večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Replagal’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zaključil je, da so koristi zdravila Replagal večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Resolor’s benefits are greater than its risks and recommended that it be given marketing authorisation..
CHMP je zaključil, da so koristi zdravila Resolor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Revlimid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Revlimid večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Revolade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Revolade večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rienso’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rienso večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rilutek’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Rilutek večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Riluzole Zentiva’s benefits are greater than its risks to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis.
Odbor CHMP je zaključil, da so koristi zdravila Riluzole Zentiva večje od z njim povezanih tveganj, kar zadeva podaljšanje življenja ali podaljšanje časa do mehanske ventilacije pri bolnikih z amiotrofično lateralno sklerozo.
The CHMP decided that Riprazo HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Riprazo HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Ristaben’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ristaben večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ristfor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ristfor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that RoActemra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila RoActemra večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Rotarix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Rotarix večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that RotaTeq’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila RotaTeq večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ruconest’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ruconest večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ryzodeg’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ryzodeg večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Scintimun’s benefits are greater than its risks.
CHMP je zaključil, da so koristi zdravila Scintimun večje od z njim povezanih tveganj.
The CHMP decided that Sebivo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Sebivo večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Selincro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Selincro večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Sifrol’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Sifrol večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Siklos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Siklos večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Silgard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Silgard večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Silodyx’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Silodyx večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Simponi’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Simponi večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that SonoVue’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila SonoVue večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Sprimeo HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Sprimeo HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Sprycel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Sprycel večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Stalevo’s benefits are greater than its risks for the treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment.
CHMP je zaključil, da so koristi zdravila Stalevo pri zdravljenju bolnikov s Parkinsonovo boleznijo in motoričnimi fluktuacijami ob koncu odmernega obdobja, ki jih zdravljenje z levodopo/zaviralci dopa dekarboksilaze ne stabilizira, večje od z njim povezanih tveganj.
The CHMP decided that Stocrin’s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older.
CHMP je zaključil, da so koristi zdravila Stocrin pri kombiniranem protivirusnem zdravljenju odraslih, mladostnikov in otrok, starih tri leta ali več, okuženih z virusom HIV, večje od z njim povezanih tveganj.
The CHMP decided that Sustiva’s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents and children three months of age and older.
CHMP je zaključil, da so koristi zdravila Sustiva pri kombiniranem protivirusnem zdravljenju odraslih, mladostnikov in otrok, starih tri mesece ali več in okuženih z virusom HIV, večje od z njim povezanih tveganj.
The CHMP decided that Sutent’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Sutent večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Sycrest’s benefits are greater than its risks and recommended that it be given marketing authorisation for the treatment of moderate to severe manic episodes in patients with bipolar disorder.
CHMP je zaključil, da so koristi zdravila Sycrest večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet za zdravljenje zmernih do hudih maničnih epizod pri bolnikih z bipolarno motnjo.
The CHMP decided that Synagis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Synagis večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that TachoSil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila TachoSil večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Tamiflu’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Tamiflu večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Tarceva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Tarceva večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Tasigna’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Tasigna večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Tasmar’s benefits are greater than its risks in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other COMT inhibitors.
CHMP je sklenil, da so koristi zdravila Tasmar v kombinaciji z levodopo/benserazidom ali levodopo/karbidopo za uporabo pri bolnikih z idiopatsko Parkinsonovo boleznijo, odzivno na levodopo, in motoričnimi nihanji, ki se niso odzvali na druge zaviralce encima COMT ali pa jih ne prenašajo, večje od z njim povezanih tveganj.
The CHMP decided that Taxotere’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Taxotere večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Temodal’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Temodal večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Tesavel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Tesavel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Teysuno’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Teysuno večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that the benefits of Eliquis are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Eliquis večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that the benefits of Ioa are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ioa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that the benefits of Soliris are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Soliris večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that the benefits of Somavert are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Somavert večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that the medicine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zaključil je, da so koristi zdravila večje od z njim povezanih tveganj, zato je priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that the vaccine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je sklenil, da so koristi cepiva večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that the vaccine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi cepiva večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Thyrogen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Thyrogen večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Torisel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Torisel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.